Hexagon Nutrition Limited – Investor Presentation Summary

Key Operational Highlights

  • Company operates 4 manufacturing plants across India and Uzbekistan with 600+ permanent staff
  • Products exported to 80+ countries across 5 continents with 400+ domestic distributors and 20 international distributors
  • Manufacturing capacity includes: Nashik plant (Dry: 135 MT, Liq: 12.5 MT, RUF: 200 MT, Clinical: 110 MT), Chennai plant (Dry: 425 MT, Liq: 30 MT, MNP: 31.5 MT), Thoothukudi plant (RUF: 480 MT per month), Uzbekistan plant (Dry: 275 MT, MNP: 4 MT)
  • 55% repeat customers including FMCG majors, hospitals, and UN agencies
  • 6.5% of B2C business now through online channels

Key drivers of operational performance: Expanded international presence, diversified nutrition business, integrated manufacturing capabilities

Segment-wise Performance

  • Company operates across multiple segments: Micronutrient Premixes, Clinical Nutrition, Therapeutic Nutrition, Wellness Nutrition
  • B2C Clinical Nutrition includes Pentasure brand with 12+ clinical SKUs for diabetic, renal, dialysis, hepatic, critical care
  • B2C Wellness Nutrition includes Pediagold for pediatric nutrition and Obesigo for weight management
  • International business spans 80+ countries across Africa, Southeast Asia, Middle East, Latin America, Pacific regions

Explanation of significant changes in segment performance: Growth driven by diversified nutrition business across multiple segments and geographies

Financial Highlights

Revenue: ₹1,096.61 Mn (Q2 FY27), ₹2,139.67 Mn (H1 FY27)

EBITDA: ₹108.60 Mn (Q2 FY27), ₹226.61 Mn (H1 FY27)

PAT: ₹81.65 Mn (Q2 FY27), ₹162.38 Mn (H1 FY27)

EPS: Basic EPS ₹0.74 (Q2 FY27), ₹1.41 (H1 FY27); Diluted EPS ₹0.66 (Q2 FY27), ₹1.32 (H1 FY27)

Margins: EBITDA Margin 9.90% (Q2 FY27), 10.59% (H1 FY27); PAT Margin 7.45% (Q2 FY27), 7.59% (H1 FY27)

YoY/QoQ comparison: Q2 FY27 revenue grew 15.21% YoY; H1 FY27 revenue grew 27.33% YoY; PAT decreased YoY in Q2 but maintained similar H1 levels

Drivers of financial performance: Higher revenue growth offset by increased cost of materials consumed and other expenses

Key Risks: Raw material price fluctuations, regulatory changes, regional market gaps

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Products exported to Africa (Ethiopia, Rwanda, South Africa, Nigeria, Ghana, Kenya, Madagascar, Mozambique, Cote D'Ivoire, Uganda, Zimbabwe, Cameroon), Southeast Asia (Malaysia, Indonesia, Philippines, Vietnam, Bangladesh, Myanmar, Thailand, Papua New Guinea), Middle East (UAE, Qatar, Saudi Arabia, Oman, Jordan, Israel, Kuwait), Latin America (Brazil, Paraguay, Peru, Mexico, Colombia, Ecuador), Pacific & Others (French Polynesia, Mauritius, Australia, New Zealand, USA, France)

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Current Assets ₹2,818.25 Mn (H1 FY27), Current Liabilities ₹997.83 Mn (H1 FY27)

Working Capital/Leverage Metrics: Inventories ₹1,361.45 Mn (H1 FY27), Trade Receivables ₹766.45 Mn (H1 FY27), Cash & Equivalents ₹142.82 Mn (H1 FY27)

Financial Health Insights: Total Assets increased to ₹3,582.78 Mn from ₹3,184.03 Mn (FY26), Total Equity at ₹2,449.62 Mn (H1 FY27)

Capex & Cash Flow Health

Capital Expenditure: Not Specified

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Focus on capacity expansion, technology upgrades, and operational efficiencies

Strategic & R&D Initiatives

Investments in Innovation: 2 R&D centres (Nashik + Chennai) with 11-member team, 9 products in R&D pipeline, HEXA VIT A+ stable Vitamin A Palmitate for food fortification

Expected impact on growth: New product development cycle typically 6 months to 2 years

Strategic Rationale: Expanding into high-growth markets, developing innovative nutrition solutions, leveraging integrated manufacturing capabilities

Industry Trends & Business Environment

Macro/Industry Trends: India nutrition market estimated at ₹1,338 Bn (CY24) growing to ₹2,814 Bn (CY30P) at ~13% CAGR; Clinical nutrition market at ₹55,724 Mn (CY24) growing to ₹1,12,058 Mn (CY30P) at 12.3% CAGR; Rising health awareness, higher disposable incomes, government fortification mandates

Impact on Company: Favorable policy environment with POSHAN 2.0 extended to 2026, rice fortification mandated in 15+ states; Rising demand for disease-specific clinical nutrition due to aging population and chronic diseases

Management Commentary & Growth Outlook

Strategic Outlook: Focus on expanding international presence, strengthening domestic distribution network, developing innovative high-value nutrition solutions

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Improving operational efficiencies and strengthening profitability remain key focus areas; Committed to enhancing product portfolio and expanding market reach